Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensity Modulated Radiotherapy with Simultaneous Boost plus Temozolomide in High-Grade Gliomas
2008-003714-10Phase 2Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Mar 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in high-grade glioma (HGG), sponsored by Policlinico Gemelli. Primary endpoint: global survival. Started Mar 2009; status: terminated.
02
Drugs
temozolomide
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on 2008-003714-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003714-10.